Navigation Links
Merck Serono Named as a Top Employer by Science Magazine
Date:10/9/2008

tions as employers.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R)), multiple sclerosis (Rebif(R)), infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)).

With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.1 billion in 2007, a history that began in 1668, and a future shaped by 31,946 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.net or http://www.merck.de


'/>"/>
SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
4. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
5. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
9. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
10. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
11. EMD Serono Named as a Top Employer by Science Magazine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ewswire-FirstCall/ -- BioSpecifics Technologies Co...developing first-in-class collagenase-based produc...third quarter ended September 30, 2009. ,, "We...ear, the FDA,s Arthritis Advisory Committee unanim... of XIAFLEX(TM) for the treatment of Dupuytren,s d...
(Date:11/6/2009)... 6 Calbiotech, Inc. announced toda...tive Research (SBIR) Phase I contract by the U.S. ...terms of the agreement, Calbiotech will develop an...f Dengue virus. ,, Dengue virus is a mosquit...o military forces deployed to tropical areas of th...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
(Date:11/5/2009)..., November 5, 2009 at 4:30 p.m. Eastern Time ,,...stCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGe...rted unaudited financial results for the third qua...reviewed the Company,s highlights for the third qu...sults reflect the operations of OncoGenex Technolo...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...ers for Medicare and Medicaid Services (CMS) issue...emporary Total Artificial Heart (TAH-t) through th...S-DRG 001 and 002. In addition, CMS also approved ... add-on payments for FY 2009, which starts Oct. 1,...Business Wire EON) August 7, 2008 -- On May 1, 20...
...arch in,Music Medicine, Inc. (ARIMM) announced tod... held September 12-13, 2008, at the Indiana,Univer... For online registration and more information, vis...ear,s conference theme is ,Music and Medicine: Com...Salle, the co-founder and Chairman,of the Board fo...
...Pink Sheets: AIMM) today reported a net loss of $8...he three months ended June 30, 2008, compared with...sic and diluted, for the,three months ended June 3...e net loss was $193,000, or $0.01 per share basic ... break even per share basic and diluted for the,sa...
Other Biology Technology: CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments 2The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:11/3/2009)...November 4, 2009) For more than 25 years, all att...trombus gigas ) have been unsuccessfuluntil now. F...echniques to produce beaded (nucleated) and non-be...n developed by scientists from Florida Atlantic Un...HBOI). With less than two years of research and ex...
(Date:11/3/2009)... research report published in a recent issue of H... Alegre examined the effects of covering orchard f...quality, canopy light distribution, orchard temper...formed using Extenday and Solarmate films installe... ,Mondial Gala, apples. The research showed that t...
(Date:11/3/2009)...Obese women are as much as 28 percent less likely ..., according to research that earned a Michigan Sta...findings by Barbara Luke, a researcher in the MSU ...cs, Gynecology and Reproductive Biology, focused o...ductive technology. , Luke,s findings, which als...
Breaking Biology News(10 mins):Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Reflective film can boost profits for apple growers 2MSU researcher: Obesity significantly cuts odds of successful pregnancy 2First Annual Congressional Womens Softball Game to Benefit the Young Survival Coalition 51209 1First Annual Congressional Womens Softball Game to Benefit the Young Survival Coalition 51209 2First Annual Congressional Womens Softball Game to Benefit the Young Survival Coalition 51209 3Conning Research 3A Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011 51207 1Conning Research 3A Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011 51207 2Calcium Isnt the Secret to Healthy Bones Says Natural Solutions Magazine 51205 1Calcium Isnt the Secret to Healthy Bones Says Natural Solutions Magazine 51205 2
...s, jellyfish - have the simplest eyes that exist. ...eptor cell and a pigment cell. These minimal eyes,...ted by Charles Darwin as the first eyes to appear ...llow the animal to sense the direction of light. T...g towards light exhibited by many zooplankton larv...
...spital have gained new insights into regulation of...ns. , As the cell,s molecular overachievers, cal...ng the movement of cells in tissues, the death of ...nd muscle function. The downside of this broad set...ve calpains have been linked to an array of disord...
...forming clouds to the flow of the molten Earth,s c...ngine to the coursing blood in your veins, from th...icroscopic animals in the ocean, many of nature,s .... , The 61st Annual Meeting of the American Physi...kes place from November 23-25 at the San Antonio C...
Other Biology News:Uncovering secrets of life in the ocean 2New insight into the controls on a go-to enzyme 2New insight into the controls on a go-to enzyme 3The physics of star-forming clouds and the urban environment 2The physics of star-forming clouds and the urban environment 3The physics of star-forming clouds and the urban environment 4The physics of star-forming clouds and the urban environment 5The physics of star-forming clouds and the urban environment 6
...satile power supply. Capable of producing up to 50...eal for PAGE, SDS-PAGE, DNA or RNA submarine gels ...ratus. It is designed to operate in constant volta...e output in either mode. The EC135-90 automaticall...
Micropipette Beveler Basic System from AutoMate Scientific, Inc
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
RCF (R306-05) from European Collection of Cell Cultures (ECACC)
Biology Products: